Implications of P-glycoprotein for the Transport and Distribution of Drugs into the Brain

Blood-Spinal Cord and Brain Barriers in Health and Disease

Volumn , Issue , 2004, Pages 63-72

  van der Sandt, Inez C J ^a   De Boer, Albertus G ^a   Breimer, Douwe D ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34347378293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012639011-7/50011-5     Document Type: Chapter

References (113)

1. Abbott N.J., Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996, 2(3):106-113.
2. Adreana A., Aggarwal S., Gollapudi S., Wien D., Tsuruo T., Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDRI gene, a metabolically active efflux pump in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 1996, 12(15):1457-1462.
3. Alsenz J., Steffen H., Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 1998, 15:423-428.
4. Asaba H., Hosoya K., Takanaga H., Ohtsuki S., Tamura E., Takizawa T., Terasaki T. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J. Neurochem. 2000, 75(5):1907-1916.
5. Borst P., Schinkel A.H. What have we learnt thus far from mice with disrupted P-glycoprotein genes. Eur. J. Cancer 1996, 32A(6):985-990.
6. Bradbury M.W. The structure and function of the blood-brain barrier. Fed. Proc. 1984, 43(2):186-190.
7. Brightman M.W., Reese T.S. Junctions between intimately opposed cell membranes in the vertebrate brain. J. Cell. Biol. 1969, 40:648-677.
8. Callaghan R., Riordan J.R. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 1993, 268:16059-16064.
9. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaeffeler E., Eichelbaum M., Brinkmann U., Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDRI gene in white subjects. Clin. Pharm. Ther. 2001, 69(3):169-174.
10. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
11. Chong A.S. Divers multidrug-resistance-modification agents inhibit cytolic activity of natural killer cells. Cancer Immunol. Immunother. 1993, 36:133-139.
12. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HOC-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 1997, 94:13193-13197.
13. Cordon-Cardo C.J., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86:695-698.
14. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol. 1989, 9:1246-1250.
15. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie S., Binkley S.N., Kuhfeld M.T., Starling J.J., Wrighton S.A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 1999, 290:854-862.
16. De Vries E. Characteristics of the Blood-Brain Barrier Endothelial Cells in Response to Inflammatory Stimuli. Ph.D. thesis, section IV 1995, Leiden University, The Netherlands.
17. Dey S., Ramachandra M., Pastan I., Gottesman M.M., Ambudkar S.V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA 1997, 94:10594-10599.
18. 3H]verapamil radioligand-binding assay. J. Pharmacol. Exp. Ther. 1999, 288:348-357.
19. Dorsey B.D., Levin R.B., McDaniel S.L., Vacca J.P., Guare J.P., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Quintero J.C., Lin J.H., Chen I.W., Holloway M.K., Fitzgerald P.M.D., Axel M.G., Ostovic D., Anderson P.S., Huff J.R. 1.735 524. The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37:3443-3451.
20. Ehrlich P. Das Sauerstoffbedeuerfnis des Organismus; eine farbenanalytische Studie 1885, Hirschwald, Berlin.
21. Fath M.J., Kolter R. ABC-transporters: The bacterial exporters. Microbiol. Rev. 1993, 57:995-1017.
22. Field F.J., Born E., Chen H., Murthy S., Mathur S.N. Esterification of plasma membrane cholesterol and triacylglycerolrich lipoprotein secretion in Caco-2 cells: A possible role of P-glycoprotein. J. Lipid. Res. 1995, 36:1533-1543.
23. Fischer V., Rodríquez-Gascón A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A.E.M. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 1998, 26(8):802-811.
24. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 1998, 87(3):306-310.
25. Goldmann E.E. Die aussere und innere Sekretion des gesunden und kranken Organismus im Lichte der vitalen Farbung. Beitr. Klin. Chirurg. 1909, 64:192-265.
26. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 1995, 29:607-649.
27. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. biochem. 1993, 62:385-427.
28. Gottesman M.M., Pastan J. Drug resistance: Alterations in drug uptake or extrusion. Encyclopedia of Cancer 1996, 549-559. Academic Press, San Diego. J.R. Bertino (Ed.).
29. Gramatté T., Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 1999, 66:239-245.
30. Gramatté T., Oertel R., Terhaag B., Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 1996, 59:541-549.
31. Gros P., Ben Neriah Y., Croop J., Housman D.E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986, 323:728-731.
32. Gupta S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: A role in cytotoxic effector function. J. Clin. Immunol. 1992, 12:451-458.
33. Hendrikse N.H., Schinkel A.H., De Vries E.G.E., Fluks E., Van der Graaf W.T.A., Willemsen A.T.M., Vaalburg W., Fransen E.J.F. Complete in vivo reversal of P-glycoprotein function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 1998, 124:1413-1418.
34. Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 9:736-749.
35. Higgins C.F. ABC transporters: From microorganisms to man. Annu. Rev. Cell Biol. 1992, 8:67-113.
36. Hipfner D.R., Deeley R.G., Cole S.P. Structural, mechanistic and clinical aspects of MRPI. Biochim. Biophys. Acta 1999, 1461:359-376.
37. Hofmeyer S., Burk O., Van Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000, 97(7):3473-3478.
38. Hori R., Okamura N., Aiba T., Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 1993, 266:1614-1619.
39. Horio M., Chin K.V., Currier S.I., Goldenberz S., Williams C., Pastan I., Gottesman M.M., Handler J. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 1989, 5:14880-14884.
40. Hosoya K., Asaba H., Terasaki T. Brain-to-blood efflux transport of estrone-3-sulfate at the blood-brain barrier in rats. Life Sci. 2000, 67(22):2699-2711.
41. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M., Beijnen J.H., Schinkel A.H. P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 2001, 59(4):806-813.
42. Hunter J.H., Hirst B.H., Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 1993, 10:743-749.
43. Hunter J.H., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 1993, 268:14991-14997.
44. Idriss H.T., Hannun Y.A., Boulpaep E., Basavappa S. Regulation of volume-activated chloride channels by P-glycoproptein: Phosphory lation has the final say. J. Physiol. 2000, 524(3):629-636.
45. Ito S., Woodland C., Harper P.A., Koren G. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PKI). Life Sci. 1993, 53:399-403.
46. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56:988-994.
47. Jonker J.W., Wagenaar E., Van Deemter L., Gottschlich R., Bender H.M., Dasenbrock J., Schinkel A.H. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol. 1999, 127(1):43-50.
48. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hanster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
49. Kamimoto Y., Gatmaitan Z., Hsu J., Arias I.M. The function of Gp 170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem. 1989, 264:11693-11698.
50. Karlsson J., Kuo S.M., Ziemniak J., Artursson P. Transport of celliprolol across human intestinal epithelial (Caco-2) cells: Mediastion of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 1993, 110:1009-1016.
51. Karssen A.M., Meijer O.C., Van der Sandt I.C.J., Lucassen P.J., De Lange E.C.M., De Boer A.G., De Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001, 142(6):2686-2694.
52. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101:289-294.
53. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J.J., Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16:408-414.
54. Konig J., Nies A.T., Cui Y., Leier I., Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1999, 1461:377-394.
55. Lan L.B., Dalton J.T., Schuetz E.G. Mdr limits CYP3A metabolism in vivo. Mol. Pharm. 2000, 58:863-869.
56. Leahy D.E., Lynche J., Taylor D.D. Mechanisms of absorption of small molecules. Novel Drug Delivery 1989, 33-44. Wiley, New York. L.F. Presscott, W.S. Nimmo (Eds.).
57. Lee C.G., Gottesman M.M. Editiorial HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Inv. 1998, 101(2):287-288.
58. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
59. Lennemäs H., Regard C.G. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm. Res. 1993, 10:727-731.
60. Letrent S.P., Pollack G.M., Brouwer K.R., Brouwer K.L.R. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphin in the rat. Drug Metab. Dispos 1999, 27(7):827-834.
61. MacFarland A., Abramovich D.R., Ewen S.W., Pearson C.K. Stage-specific distribution of P-glycoprotein in firsttrimester and full-term human placenta. J. Histochem. 1994, 26:417-423.
62. Martin C., Berridge G., Higgins C.F., Callaghan R. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br. J. Pharmacol. 1997, 122(4):765-771.
63. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 2000, 58:624-632.
64. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., Van Asperen J., Borst P., Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br. J. Pharmacol. 1996, 119:1038-1044.
65. Mayer U., Wagenaar E., Dorobek B., Bijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 1997, 100:2430-2436.
66. McLay R.N., Kimura M., Banks W.A., Kastin A.J. Granulocyte-macrophage colony stimulating factor crosses the blood-brain and blood-spinal cord barriers. Brain 1997, 120:2083-2091.
67. Okamura N., Hirai M., Tanigawara Y., Tanaka K., Yasuhara M., Ueda K., Komato T., Hori R. Digoxin-cyclosporin A interaction: Modulation of the multidrug trasnporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther. 1993, 266:1614-1625.
68. Pardridge W.M. Brain metabolism: A perspective from the blood brain barrier. Physiol. Rev. 1983, 63:1481-1535.
69. Pardridge W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997, 17:713-731.
70. Pearce H.L., Safa A.R., Bach N.J., Winter M.A., Cirtain M.C., Beck W.T. Essential features of the Pgp pharmacophore as defined by a series of reserpine analogs that modulate multidrug resisitance. Proc. Natl. Acad. Sci. USA 1989, 86:5128-5132.
71. Peters W.H.M., Roelofs H.M.J. Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: A possible role for gluthatione S-transferases. Cancer Res. 1992, 52:1886-1890.
72. Pigeon R.P., Silver R.P. Topological and mutational analysis of KpsM, the hydrophobic component of the ABC-transporter involved in the export of polysialic acid in Escherichia coli K1. Mol. Microbiol. 1994, 14:871-881.
73. Resnick L., Berger J.R., Shapshak P., Tourlotte W.W. Early penetration of the blood-brain barrier by HIV. Neurology 1998, 38:9-14.
74. Riddell J.G., Shanks R.G., Brogden R.N. Celiprolol: A preliminary review of its pharmacodynamic properties and its therapeteutic use in hypertension and angina pectoris. Drugs 1998, 34:438-458.
75. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., Van Deemter L., Smit J.J.M., Van der Valk M.A., Voordouw A.C., Spits H., Van Tellingen O., Zijlmans J.M.J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 1997, 94:4028-4033.
76. Schinkel A.H., Mol C.A.A.M., Wagenaar E., Van Deemter L., Smit J.J.M., Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 1995, 31:1295-1298.
77. Schinkel A.H., Smith J.J.M., Van Tellingen O., Beijnen J.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Van der Valk M.A., Robanus-Maandag E.C., Te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdrla P-glycoprotein leads to a deficiency in the blood brain barrier and to mcreased sensitivity to drugs. Cell 1994, 77:491-502.
78. Schikel A.H., Wagennar E., Mol C.A.A.M., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97(11):2517-2524.
79. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Inv. 1995, 96(4):1698-1705.
80. Schuetz E.G., Furuya K.N., Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 1995, 275:1011-1018.
81. Schuetz E.G., Schinkel A.H., Relling M.V., Schuetz J.D. P-glycoprotein: A major determinant of rifampicin-inducible expression of hepatic cytochromes P450 in mice and humans. Proc. Natl. Acad. Sci. USA 1996, 93:4001-4005.
82. Schuetz E.G., Umbenhauer D.R., Yasuda K., Brimer C., Nguyen L., Relling M.V., Schuetz J.D., Schinkel A.H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdrl genes. Mol. Pharmacol. 2000, 57:188-197.
83. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1998, 251:252-261.
84. Shapiro A.B., Fox K., Lam P., Ling V. Stimulaltion of P-glycoprotein-mediated drug transport by prazosin and progesterone: Evidence for a third drug-binding site. Eur. J. Biochem. 1999, 259:841-850.
85. Soldner A., Christians U., Susanto M., Wacher V.J., Silverman J.A., Benet I.Z. Grapefuit juice activates P-glycoproteinmediated drug transport. Pharm. Res. 1999, 16(4):478-485.
86. Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Tethaag.B., Ader P., Hanafy A., Langguth P. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 1998, 36:16-24.
87. Sparreboom A., Van Aseren J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., Van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 1997, 94:2031-2035.
88. Speeg K.V., Maldonado A.L. Effect of cyclosporine on colchicine partitoning in rat liver. Cancer Chemother. Pharmacol. 1993, 32:434-436.
89. Speeg K.V., Maldonasdo A.L. Effect of the nonimmunosuppressive cyclosporine on colchienie partitioning in rat liver. Cancer Chemother. Pharmacol. 1994, 32:434-436.
90. Speeg K.V., Maldonado A.L. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin in biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol. 1994, 34:133-136.
91. Sugawara I., Kutaoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988, 48:1926-1929.
92. Takanaga H., Ohnishi A., Matsuo H., Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharmacol. Bull. 1998, 21(10):1062-1066.
93. Tanabe M., Ieiri L., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (mdr)-1 gene. J. Pharmacol. Exp. Ther. 2001, 297(3):1137-1143.
94. Tardieu M. HIV-1-related central nervous system diseases. Curr. Opin. Nearol. 1999, 12(4):377-382.
95. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA 1987, 84:7735-7738.
96. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad Sci. USA 1987, 84:3004-3008.
97. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem 1992, 267:24248-24252.
98. Van der Sandt I.C.J., Blom-Roosemalen M.C.M., De Boer A.G., Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharom. Sci. 2000, 11:207-214.
99. 1A receptor agonist flexinoxan via P-glycoprotein at the blood-brainbarrier. Eur. J. Pharm. Sci. 2001, 14:81-86.
100. Van der Sandt J.C.J., Vos C.M.P., Nabulsi L.M., Blom-Roosemalen M.C.M., Voorwinden L.H., De Boer A.G., Breimer D.D. Assessment of active transport of HIV protease inhibitiors in various cell lines and the in vitro blood-brain barrier. AIDS 2001, 15(4):483-491.
101. Van Kalken C., Giaccone G., Van der Valk P., Kuiper C.M., Hadisaputro M.M., Bosma S.A., Scheper R.J., Meijer C.J., Pinedo H.M. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. 1992, 141:1063-1072.
102. Vilaboa N.E., Galan A., Troyano A., De Blas E., Aller P. Regulation of multidrug resistance 1(MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J. Biol. Chem. 2000, 275(32):24970-24976.
103. Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem. Biophys. Res. Commun. 2000, 276(3):909-916.
104. Watanabe T., Miyauchi S., Sawada Y., Iga T., Hanano M., Inaba M., Sugiyama Y. Kinetic analysis of hepatobiliary transport of vincristine. J Hepatol. 1992, 16:77-88.
105. Watkins P.B., Wrighton S.A., Maurel P., Schuetz E.G., Mendez-Picon G., Parker G.A., Guzelian P.S. Idenfitification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 1985, 82:6310-6314.
106. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., Von Richter O., Warzok R., Hachenberg T., Kauffman H.M., Schrenk D., Terhaag B., Kroemer H.K., Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction. Clin. Pharm. Ther. 2000, 68(4):345-355.
107. Wrighton S.A., Vandenbranden M., Ring B.J. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 1996, 24:461-473.
108. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance transporter. J. Biol. Chem. 1988, 269:15973-15976.
109. Zhang L., Sachs C.W., Fu H.W., Fine R.L., Casey P.J. Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. J. Biol. Chem. 1995, 270:22859-22865.
110. Zhang Z.J., Saito T., Kimura Y., Sugimoto C., Ohtsubo T., Saito H. Disruption of mdrla p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice. Brain Res. 2000, 852(1):116-126.
111. Zhang Y., Han H.Y., Elmquist W.F., Miller D.W. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 2000, 876(1-2):148-153.
112. Zhang Y., Benel L.Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001, 40(3):159-168.
113. Zong J., Pollack G.M. Morphine antinociception is enhanced in mdrla gene-deficient mice. Pharm. Res. 2000, 17(6):749-753.